14 results about "Balanced salt solution" patented technology

The primary culture method of the porcine ovary granular cells comprises the following steps: step 1, taking a fresh porcine ovary, quickly putting the porcine ovary into a Hank's balanced salt solution preheated at 38 DEG C for transportation, repeatedly washing the ovary with the Hank's balanced salt solution to remove blood and impurities, and then extracting follicular fluid with a 5ml syringe under a sterile condition; according to the method, the granular cells can be effectively separated and cultured from the porcine ovary, and the porcine ovary granular cells with higher purity and better activity can be obtained, so that the subsequent cell biology experiment research, such as gene transfection, protein expression analysis and the like, is facilitated; a cell model is provided for researching the physiological functions (such as hormone secretion and follicle development regulation and control) of the porcine ovarian granular cells, the operation is relatively simple, the cost is relatively low, and the used reagents and instruments are common in a cell culture laboratory and are convenient to popularize and apply.

The present invention relates to an ophthalmic ultrasonic emulsification sleeve for confirming intraocular and extraocular penetration and perfusion, which allows determining whether aqueous humor communication between the inside and outside of the eye is smooth through a microtube implanted in the eye during glaucoma tube surgery. The sleeve is characterized by having a rigid branch tube made of a material harder than a sleeve made of a soft material, provided in a perfusion port that allows the injection of a balance salt solution into the eye, and with the branch tube connected to the perfusion port, the tip of the branch tube protrudes further than the tip of the Paco tip, and the end of the microtube inside the eye is connected to the tip of the branch tube, so that the establishment of aqueous humor communication of the microtube can be quickly and accurately and sensorially confirmed based on the pattern of pressure change in the conjunctival area and surrounding blood flow change that occurs when the balance salt solution leaks out of the eye.

This invention discloses a detection kit and identification method for CTCs based on SCLC molecular typing using microfluidic chips and multiplex immunofluorescence probe technology. The kit includes a microfluidic chip, a biotin-labeled trapping agent, a balanced salt solution, a tissue cell fixation solution, a specific hybridization blocking solution, an active nuclear staining solution, and a diluent. It also includes a detection agent composed of key subtype markers of SCLC labeled with different fluorescein groups, SCLC-related marker detection antibodies, and leukocyte auxiliary identification markers, or a detection agent composed of key subtype markers of SCLC labeled with different fluorescein groups and leukocyte auxiliary identification markers. This application enables non-invasive, early, and sensitive detection and analysis of the expression of four immunomarkers involved in CTCs in the peripheral blood of patients: ASCL1, NEUROD1, POU2F3, and YAP1. It is suitable for early tumor screening and can also be used for pan-cancer immunotherapy guidance, immunotherapy efficacy monitoring, and prognostic assessment.

The present invention belongs to the technical field of medical devices, and in particular relates to a tooth fixing device and method for autologous tooth transplantation or replantation, comprising a clamping device and a storage bag. The ex vivo tooth is immersed in a Hank's balanced salt solution in the storage bag, and the ex vivo tooth is fixed upside down in the clamping device through the storage bag. During the process of fixing the ex vivo tooth and operating the tooth root of the ex vivo tooth, the ex vivo tooth is always in the Hank's balanced salt solution, so that the ex vivo tooth is placed in a sterile environment, the activity of the periodontal membrane is maintained to the greatest extent possible, and the root surface is kept clean to prevent the adhesion of gutta-percha and debris, thereby improving the success rate of tooth transplantation and tooth replantation.

An anterior chamber maintainer (ACM), which is to be utilized in connection with maintaining physiological intraocular pressure during intraocular surgery, is disclosed and comprises an axially elongated tubular member which is adapted to be fluidically connected at a first end to a supply of balanced salt solution (BSS) for introduction into the anterior chamber of an eye so as to maintain adequate intraocular pressure while performing any intraocular surgery. A second opposite end of the anterior chamber maintainer (ACM) is provided with a sharply pointed end for insertion through a paracentesis incision formed within the limbus region of the eye, and a non-deformable, incompressible, tapered, annular bulbous portion is interposed between the first and second ends such that as the second end passes through the paracentesis incision, the non-deformable, incompressible, tapered, annular bulbous portion will cause the paracentesis incision to deform or expand radially outwardly, and after passing through the paracentesis incision, the non-deformable, incompressible, annular bulbous portion will trap the anterior chamber maintainer (ACM) within the anterior chamber of the eye.

The invention relates to a compatibility method of a retinal pigment epithelial cell cryopreservation preparation, which comprises the steps of dilution, balancing, washing and compatibility: 1) a dilution step: preparing a diluted solution which comprises a balanced salt solution (for perfusion), preferably, the diluted solution further comprises a compound amino acid injection; 2) a balancing step: resuscitating cells in the RPE cell cryopreservation preparation, then mixing the cells with the prepared diluted solution, and standing for balancing; (3) washing: centrifuging the solution, absorbing and discarding the supernate, adding a balanced salt solution (for perfusion), resuspending the cells, centrifuging, and absorbing and discarding the supernate; and 4) a compatibility step: adding a balanced salt solution (for perfusion) into the cell precipitate, and adjusting the cell to a required density according to a living cell density result.

The present invention relates to a culture medium for efficiently and rapidly culturing primary mouse pulmonary artery endothelial cells, belonging to the technical field of culture medium preparation, and well solving the problems such as high price, slow cell crawling speed and poor cell state of the primary mouse pulmonary artery endothelial cell culture medium on the current market. The culture medium comprises the following components: glucose, L-glutamine, sodium pyruvate, sodium bicarbonate, fetal bovine serum, heparin, vascular endothelial growth factor, epidermal growth factor, vasopressin, endothelin, phenol red, Earle's balanced salt solution, and ultrapure water. This culture medium can culture primary mouse pulmonary artery endothelial cells economically, rapidly and efficiently, and has the characteristics of good cell growth, stable phenotype and meeting the requirements of subsequent experiments.

A method for storing or transporting cells, tissues or organs including: preparing a cytoprotectant formulation by mixing a first precursor solution including a balanced salt solution having a pH of from 7.6 to about 8.0 and a second precursor solution comprising water, D-glucose, glutathione, ascorbic acid, and optionally L-arginine at a pH of about 3-5; extracting cells, tissues or organs during a biopsy procedure; and storing or transporting the cells, tissues or organs in the cytoprotectant formulation. The cytoprotectant formulation can also be prepared by reconstituting a powder formulation in a saline or sterile water media to form a cytoprotectant formulation, where the powder formulation includes a reducing agent, an antioxidant, a sugar, a buffering agent, physiologically acceptable salts, optionally a nitric oxide substrate, and is reconstituted at a point of use in a saline or sterile water media.

The invention provides a method for separating extracellular vesicles from populus euphratica alkali and application of the extracellular vesicles to nerve cell injury, and the separation method comprises the following steps: crushing populus euphratica alkali into powder, adding into a balanced salt solution, placing in a shaking table, and oscillating overnight; carrying out rough filtration, centrifugation and fine filtration on the obtained solution to remove large-particle impurities in the solution; and separating the extracellular vesicles from the obtained filtrate in an ultracentrifugation manner. According to the invention, the extracellular vesicles are separated from the populus diversifolia alkali, and the separated extracellular vesicles of the populus diversifolia alkali can inhibit hydrogen peroxide induced SHSY5Y nerve cell apoptosis after being swallowed by cells, so that the effect of inhibiting generation of active oxygen in the cells is very remarkable; the protection effect can realize prevention and treatment of the populus euphratica alkali extracellular vesicles on neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and the like, and can promote rapid development of research and development of drugs for preventing and treating neurodegenerative diseases.

The present disclosure relates generally to systems and methods for laser power measurement, and more particularly to systems and methods for laser power measurement in a sterile operating environment. In certain embodiments described herein, power measurements are performed with two laser sources: 1) a first laser source configured to generate a first laser beam (treatment laser); and 2) a second laser source configured to generate a second laser beam (test laser). The first laser beam generates bubbles in a test material (e.g., water, brine, equilibrium salt solution, gel, etc.), and the second laser beam is reflected back, where the reflected portion of the second laser beam is measured to determine the lifetime of the bubbles and associate lifetime measurements with power measurements based on a correlation curve.

The present disclosure generally relates to systems and methods for laser power measurement, and more particularly, systems and methods for laser power measurement in a sterile operating environment. In certain embodiments described herein, power measurement is performed utilizing two laser sources: 1) a first laser source configured to generate a first laser beam (treatment laser); and 2) a second laser source configured to generate a second laser beam (test laser). The first laser beam generates a bubble in a test material (e.g., water, saline, balanced salt solution, gel, etc.) and the second laser beam is reflected back with the reflected portion of the second laser beam being measured to determine a lifetime of the bubble and correlate the lifetime measurement with a power measurement based on a correlation curve.

[0001] The present disclosure relates generally to systems and methods for laser power measurement, and more particularly, to systems and methods for laser power measurement in a sterile working environment. In certain embodiments described herein, power measurements are made utilizing two laser sources: 1) a first laser source configured to generate a first laser beam (a treatment laser), and 2) a second laser source configured to generate a second laser beam (a test laser). The first laser beam generates gas bubbles in a test material (e.g., water, saline, balanced salt solution, gel, etc.), and the second laser beam is reflected back, and the reflected portion of the second laser beam is measured to determine the bubble lifetime, and the lifetime measurements are correlated with power measurements based on a correlation curve.

The present invention discloses a method for removing residual pluripotent stem cells after differentiation of pluripotent stem cells. The present invention develops a method for removing residual pluripotent stem cells that is harmless to cells, has a high cost-effectiveness, and can efficiently remove residual pluripotent stem cells. The method uses a balanced salt solution that does not contain calcium ions and magnesium ions to achieve efficient removal of residual pluripotent stem cells, reduce the risk of immature teratomas, and has important clinical application value.

A tear-fluid insoluble, ocular insert adapted for insertion into the eye of a subject, which is a mammal, for the sustained release of an agent selected from a therapeutic agent, a balanced salt solution, and a mixture thereof, wherein the insert comprises a bacterial cellulose hydrogel and an aqueous solution comprising the therapeutic agent and / or balanced saline solution.